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Abstract
The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and 
mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this 
process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific 
role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein 
rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell 
proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed 
that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results 
show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in 
vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal 
cancer.
Findings
The mammalian target of rapamycin (mTOR) is a serine-
threonine kinase that regulates cell growth and prolifera-
tion in response to the availability of growth factors and
nutrients [1,2]. mTOR exists in two functionally distinct
complexes: mTORC1 and mTORC2, which have different
functions and are differentially sensitive to rapamycin [3].
mTORC1 is composed of mTOR, mLST8, PRAS40, dep-
tor and raptor and is sensitive to rapamycin. mTORC1
enhances cell growth and proliferation through various
mechanisms including synthesis of proteins and lipids as
well as reduction of autophagy. Part of the functions of
mTORC1 are mediated by the phosphorylation and acti-
vation of S6K1 and 4E-BP1, two well characterized down-
stream effectors of mTORC1 [1]. mTORC2 contains
mTOR, mLST8, mSIN1, deptor, protor-1 and rictor.
Although mTORC2 is classically insensitive to rapamy-
cin, prolonged exposure to rapamycin may also inhibit
mTORC2 activity by blocking its assembly in certain cell
types [4]. In contrast to mTORC1, relatively little is
known about the functions of mTORC2. It has been
described that mTORC2 regulates cell survival and
cytoskeletal organization through the regulation of Akt
and PKCα respectively [5,6].
Since mTOR plays a major role in cell growth and pro-
liferation, targeting mTOR in cancer therapy has been
viewed as a promising approach [3,7]. Indeed, alterations
of mTOR signaling pathway are commonly observed in
solid tumors. Whereas the role of mTORC1 in cancer
progression has been extensively characterized, the role
of mTORC2 is much less documented. So far it has been
shown that targeting mTORC2 might be beneficial in
tumors harboring high levels of activated Akt, such as
gliomas or tumors caused by PTEN deletion [8,9]. Since
the activation of Akt is frequently observed in colorectal
cancer [10], we wish here to analyse the role of mTORC2
in colon cancer.
To investigate the role of mTORC2 in colon cancer, we
used a lentiviral short hairpin RNA (shRNA) expression
system that suppresses the expression of rictor to block
the activity of mTORC2 [5]. In addition we also sup-
pressed the expression of raptor to block mTORC1 or the
expression of mTOR to block both complexes. HT29 and
LS174T colon cancer cells were infected with lentiviruses
expressing either a scramble shRNA, raptor shRNA, ric-
tor shRNA or mTOR shRNA. The gene knockdown effi-
ciency following infection was analysed by Western Blot.
Using this technique, we observed that raptor, rictor and
mTOR expression was significantly reduced in both
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Page 2 of 4HT29 and LS174T cells (Figure 1A). We further observed
that mTOR and raptor downregulation reduced the phos-
phorylation of S6K1, a downstream target of mTORC1. In
addition, we also found that mTOR and rictor shRNA sig-
nificantly reduced the phosphorylation of Akt, a down-
stream effector of mTORC2. Finally, targeting raptor
increased the phosphorylation of Akt consistent with a
previously reported negative feedback loop whereby inhi-
bition of mTORC1 induces the activation of Akt (Figure
1A) [3]. These results show that mTORC1 and mTORC2
activity can be efficiently blocked by raptor or rictor
shRNA respectively in HT29 and LS174T cells. To further
document the role of mTOR in colon cancer cells, we also
treated HT29 and LS174T cells with rapamycin, a chemi-
cal inhibitor of mTORC1. Similarly to the inhibition of
mTORC1 by raptor shRNA, we found that, while block-
ing S6K1 phosphorylation, rapamycin increased Akt
phosphorylation, These results show that rapamycin
inhibits mTORC1 but not mTORC2 in HT29 and LS174T
cells (Figure 1B).
After selection by puromycin for 48 hours, we also
found that knockdown of mTOR and rictor significantly
changed the morphology of HT29 and LS174T cells.
While HT29 and LS174T cells had a small distinct cyto-
plasm and grew in cell clusters, mTOR or rictor deficient
HT29 and LS174T cells were small and round with absent
cytoplasm, and which failed to grow (Figure 2A). In con-
trast, raptor knockdown did not alter the morphology of
HT29 and LS174T cells. To exclude that the morphologi-
cal changes observed in mTOR and rictor knockdown
cells was indeed due to an increased cell death, we moni-
tored apoptosis by quantifying DNA fragmentation. We
did not find a significant change in cell apoptosis between
cells expressing scramble, raptor, mTOR or rictor shRNA
(Figure 2B).
To further characterize the role of mTORC2 in colon
cancer progression, we analyzed the effect of rictor
knockdown on colon cancer cell proliferation. We found
that the proliferation of HT29 and LS174T cells deficient
for rictor or mTOR was markedly reduced (Figure 3A).
Knockdown of raptor also significantly reduced the pro-
liferation of HT29 and LS174T cells compared to control
cells, however to a lesser extend than rictor or mTOR
knockdown. Finally, rapamycin treatment also reduced
cell proliferation to a similar extend than raptor knock-
down. To gain insight into the mechanism by which rictor
and mTOR knockdown reduced colon cancer cell prolif-
eration, we analyzed cell cycle progression using propid-
ium iodide staining and flow cytometry analysis. We
found that mTOR or rictor knockdown in LS174T cells
resulted in a G1 arrest as observed by a marked increase
in the G1 population. Similar results were observed in
HT29 cells (Figure 3B).
We next tested the effect of mTOR and rictor knock-
down on tumor growth in vivo. LS174T cells deficient for
mTOR, raptor and rictor as well as LS174T expressing a
scramble shRNA as a control were injected subcutane-
ously into nude mice and tumor growth was monitored.
Figure 1 Downregulation of mTOR, rictor and raptor in HT29 and 
LS174T colon cancer cells. (A) Knockdown of raptor, rictor or mTOR 
in HT29 (HT) and LS174T (LS). HT29 and LS174T cells were infected with 
recombinant lentiviruses containing the indicated shRNA. Two days 
post infection cells were selected for resistance to puromycin for 48 
hours. Resistant cells were plated in 6 well plates and cultured in 
DMEM 10% FBS for 2 days. Cells were subsequently lysed in RIPA lysis 
buffer containing a protease inhibitor cocktail (Sigma) and 1 mM sodi-
um orthovanadate. Proteins were quantified with the BCA protein As-
say Kit (Pierce). Equal amounts of proteins (30 μg) were resolved on 
SDS PAGE, transferred to membranes and immunoblotted with prima-
ry antibodies against mTOR, rictor, raptor, phospho-Akt (Ser 473), Akt, 
phospho-S6K1 (Thr 389) or S6K1 (Cell Signalling Technology) followed 
by infrared secondary antibodies (LI-COR Biosciences). Bands from im-
munoreactive proteins were visualised by an Odyssey infrared imaging 
system (LI-COR Biosciences). (B) Rapamycin inhibits mTORC1 but not 
mTORC2 in HT29 and LS174T cells. HT29 or LS174T cells were treated 
with rapamycin (10 ng/ml) for the indicated times. Cells were subse-
quently lysed and Western Blot analysis was performed as in A. The il-
lustrated blots are representative of three with similar findings.
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Page 3 of 4We found that mTOR or rictor deficient LS174T cells
failed to form a tumor xenograft even after 60 days of
observations (Figure 4). In contrast, LS174T cells defi-
cient for raptor formed tumor xenografts which grew
however slower than control xenografts.
Several studies have demonstrated that the activity of
mTOR is increased in tumors [7]. Particularly in colorec-
tal cancer, mTOR signaling components were highly acti-
vated in tumor specimen compared to non cancerous
mucosa [11]. Furthermore, targeting mTOR with a spe-
cific siRNA to mTOR also reduced SW480 and HCT116
colon cancer cell proliferation and survival in vitro and
injection of small interfering RNA to mTOR into
HCT116 tumor xenografts also blocked tumor growth in
vivo [11]. In addition, the inhibition of mTORC1 sup-
pressed the formation of colonic adenomas and cancers
in a mouse model of familial adenomatous polyposis [12].
Therefore, targeting mTOR in colorectal cancer might be
a successful strategy. mTOR exists in two distinct com-
plexes, however, no study so far has analyzed the specific
role of mTORC2 in colorectal cancer development. Here,
we found that mTORC2 plays an important role in colon
cancer cell proliferation. Downregulation of mTORC2, by
either blocking the expression of mTOR or rictor,
reduced the proliferation of HT29 and LS174T colon can-
cer cells in vitro and inhibited the formation of tumor
xenografts in vivo. We therefore propose that targeting
mTORC2 in colon cancer could be a promising therapeu-
tical strategy.
Targeting mTOR with rapamycin or its analogs in clini-
cal studies has been less successful than expected [7].
However, as mTORC2 and part of mTORC1 functionality
are resistant to rapamycin, one may speculate that thera-
pies that target both complexes will be much more effi-
cient in cancer therapy. Consistent with this hypothesis,
we found that the inhibition of mTORC1 reduced colon
cancer cell proliferation, however to a lesser extend than
the inhibition of both complexes, or mTORC2 alone.
Figure 2 Morphological changes induced by mTORC2 knock-
down in colon cancer cells. (A) Morphological effects of mTOR and 
Rictor downregulation in HT29 and LS174T cells. HT29 or LS174T cells 
were infected with lentiviruses expressing shRNAs targeting the indi-
cated genes. Following selection with puromycin for 48 hours, cells 
were grown on a 6 well plate for 2 or 5 additional days, and pictures 
were taken under a phase-contrast microscope at × 100 magnification. 
Scale bar: 50 μm. (B) Effects of mTOR, rictor or raptor downregulation 
on HT29 and LS174T cell apoptosis. HT29 and LS174T cells were pro-
cessed as in A. After 2 or 5 days of culture, equal amount of cells were 
harvested and apoptosis was measured by quantifying DNA fragmen-
tation using the Cell Death Detection Elisa Plus (Roche) as described by 
the manufacturer. Results are represented as the mean absorbance at 
405 nm ± standard deviations (n = 3).
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Figure 3 Effects of mTORC2 knockdown on HT29 and LS174T cell 
proliferation. (A) Knockdown of mTOR or rictor reduces the prolifera-
tion of HT29 and LS174T cells. HT29 and LS174T cells were infected 
with lentiviral particles containing scramble, raptor, rictor or mTOR 
shRNA. Forty-eight hours post-infection cells were selected for resis-
tance to puromycin for an additional 48 hours. Subsequently, 5 × 103 
cells were plated on 96 well plates and cultured in DMEM 10% FBS for 
2 or 5 days. Cell proliferation was determined by 3H-thymidine incor-
poration in the final 12 hours of cell culture. Results are expressed as 
the mean cpm ± standard deviation of three experiments. *p < 0.05 
and **p < 0.01 compared with cells expressing the scramble shRNA 
(Student's t test). (B) Knockdown of mTOR or rictor induces a G1 arrest 
in HT29 and LS174T cells. HT29 and LS174T cells were processed as in 
A. Following selection for resistance to puromycin cells were cultures 
for 2 days and subsequently collected by trypsin digestion, washed in 
PBS incubated for 24 hours in 70% ethanol. Cells were subsequently re-
suspended in PBS containing 20 μg/ml propidium iodide and 200 μg/
ml RNAse and incubated for 45 minutes at 37°C. DNA content of the 
cells was analysed with a FACScan II and the CellQUEST software (Beck-
ton Dickinson). One of three similar experiments is shown.
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Page 4 of 4Recently, several groups have developed ATP-competi-
tive and selective mTOR inhibitors that target simultane-
ously both complexes [13-15]. Initial experiments have
shown that the antiproliferative efficacy of these inhibi-
tors is superior to rapamycin [15]. Future studies will
reveal the efficacy of such inhibitors in cancer therapy;
one major concern being that these inhibitors might have
considerable toxicity in vivo. However, our results suggest
that targeting only mTORC2 might be sufficient to pre-
vent colon cancer progression and thus give a rationale
for the development of drugs that specifically target
mTORC2.
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Figure 4 Colon cancer cells require mTOR or rictor to form tumors 
as xenografts. LS174T cells were infected with lentiviral particles con-
taining scramble, raptor, rictor or mTOR shRNA. Stable transfectants 
were selected for resistance to puromycin for 48 hours and subse-
quently cultured in DMEM 10% FBS for 2 days. An equal amount (1 × 
106) of LS174T cells deficient for raptor, rictor, or mTOR, or expressing a 
scramble shRNA were harvested and injected subcutaneously into im-
munodeficient mice (n = 5 in each group). Tumor volumes were eval-
uated using calliper measurements and calculated with the formula V 
= π/6 × a2 × b where a is the short axis and b the long axis of the tumor. 
Mice bearing the scramble or the raptor shRNA xenografts were sacri-
ficed after 20 days. Mice bearing the mTOR or the rictor shRNA xeno-
grafts were observed during 60 days. Points, average value of tumor 
volume. Bars, SD. Animal experiments were in accordance with the 
Swiss federal animal regulations and approved by the local veterinary 
office. *p < 0.001 comparing with cells expressing the Scramble shRNA 
(one-way ANOVA).
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